Dishman Carbogen Amcis Limited has informed the Exchange regarding a press release dated April 21, 2025, titled "COMPANY S WHOLLY-OWNED SUBSIDIARY VIZ. CARBOGEN AMCIS (SHANGHAI) CO. LTD., RECEIVED DRUG MANUFACTURING LICENSE FROM THE NATIONAL MEDICAL PRODUCT ADMINISTRATION FOR ITS SHANGHAI SITE, CHINA".
DCAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Dishman Carbogen Amcis has informed the stock exchange that its wholly-owned subsidiary, Carbogen Amcis (Shanghai) Co. Ltd., has received a drug manufacturing license from China's National Medical Product Administration (NMPA) for its facility in Shanghai. This license authorizes the subsidiary to manufacture pharmaceutical products at the Chinese site. The approval is a key regulatory milestone that allows the company to begin commercial drug manufacturing operations in China. This strengthens the company's presence in the Chinese pharmaceutical market and expands its global manufacturing footprint.
Positive for shareholders as it unlocks commercial drug manufacturing capacity in China, opening access to one of the world's largest pharmaceutical markets and potentially driving future revenue growth from the Shanghai facility.